Mechanism of Action
Bacillus subtilis functions as a metabolic intermediary. Once its spores are activated in the intestinal tract, the bacterium resumes its activity. It then releases a range of molecules that resident strains do not produce in sufficient quantities.
It secretes digestive enzymes (proteases, lipases, amylases) that break down complex nutrients. These fragments become available to other members of the microbiota, a metabolic sharing phenomenon known as cross-feeding. It also synthesizes peptides (subtilisins) that help maintain microbial balance by limiting the space available to opportunistic bacteria.
Its metabolism generates short-chain fatty acids and vitamin K2. The former support intestinal barrier integrity. The latter plays a role in regulating local immune responses. The passage of Bacillus subtilis through the intestine is transient: it exerts its activity for several days before being naturally eliminated.
Key Benefits
- Strong
Multiple randomised controlled trials converge on a documented digestive benefit: reduction in abdominal discomfort in adult trials, and stool normalisation in 93.5% of children with antibiotic-associated diarrhea by day 3 (versus 22.6% on placebo) in a 2025 double-blind trial (n=68). The convergence across distinct populations and clinical contexts reinforces the consistency of this effect.
- Moderate
A randomized, double-blind, placebo-controlled trial in 100 adults over 60 showed that Bacillus subtilis CU1 supplementation increased secretory IgA levels (the first line of mucosal immune defense) and reduced the duration of winter respiratory infectious episodes.
- Moderate
Bacillus subtilis supplementation is associated with increased fecal microbial diversity, a parameter correlated with maintaining a functional intestinal ecosystem over the decades.
- Moderate
Bacillus subtilis naturally produces menaquinone-7 (vitamin K2) during its intestinal metabolism. This process has been documented since foundational research on natto fermentation.
- Emerging
Preliminary clinical data suggest that Bacillus subtilis supports intestinal barrier integrity through the production of short-chain fatty acids (butyrate, propionate) that nourish colonocytes (cells of the colonic mucosa).
Dosage & Forms
Probiotic supplementation faces a central challenge: viability. Vegetative strains (Lactobacillus, Bifidobacterium) lose between 60 and 90% of their population between manufacturing and arrival in the intestine. The industry works around this by overdosing (50 to 200 billion CFU listed for a few billion actually delivered) or with costly gastro-resistant coatings.
Sporebiotics bypass this problem through their biology. The Bacillus subtilis spore traverses gastric pH (1.5 to 3.5) and bile salts intact, with a documented survival rate above 95%. Dosages studied in clinical literature range from 1 to 10 billion CFU per day. Singular uses a strain concentrated at 100 billion CFU per gram. This concentration allows the target dosage to be reached with a minimal amount of powder in the daily formula.
In the Singular Formula
Inclusion rationale
Gram-positive spore-forming bacterium whose spore form resists gastric acidity, bile salts and temperature variations. This resistance allows it to reach the intestinal tract intact, where conventional probiotics in vegetative form lose a significant portion of their viability. Naturally present in soils and the human gastrointestinal tract, Bacillus subtilis has been used in human nutrition for decades, particularly in Japan in the fermentation of natto (fermented soy consumed daily for centuries). Once in the intestine, the spores germinate and resume their metabolic activity, contributing to the microbial diversity of the resident microbiota. The stability of the spore form is a decisive advantage for a powder formula stored at room temperature: no cold chain is required, and viability is preserved throughout the product's shelf life. In the formula, Bacillus subtilis integrates into a complete microbial ecosystem alongside tyndallised Bifidobacterium longum and tyndallised Akkermansia muciniphila (resident postbiotics), as well as GOS (prebiotic galacto-oligosaccharides that selectively feed bifidobacteria). This approach combining spore-forming probiotics, resident postbiotics and selective prebiotics aims to support the diversity of the intestinal microbiota, whose decline is a recognised marker of biological ageing.
Selected form
Sporebiotic Bacillus subtilis strain concentrated at 100 billion CFU per gram. Unlike conventional probiotics (Lactobacillus, Bifidobacterium), Bacillus subtilis forms spores: natural resistance structures that protect the bacterium from gastric acidity and bile, with no need for coating or refrigeration. The survival rate through to the intestine is therefore significantly higher than that of non-spore-forming vegetative forms. Spores germinate once the intestinal environment is reached. Quality: vegan, non-GMO.
Formula dosage
0 to 9 mg.
Synergies in the formula
Safety & Precautions
Bacillus subtilis has a long history of use in human nutrition. The strain is listed on the European QPS (Qualified Presumption of Safety) register. Daily consumption of natto in Japan provides centuries of usage history.
Clinical trial reports occasionally note mild digestive discomfort (bloating, flatulence) at the start of supplementation. These effects typically resolve within a few days.
Supplementation is not recommended for individuals with weakened immune defenses, as a precautionary measure. Pregnant or breastfeeding women should consult a healthcare professional before use. No notable interactions with common substances have been documented to date.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Lefevre M et al. | 2015 | Randomised Controlled Trial | Immunity & Ageing | View on PubMed |
Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study Randomized controlled trial in 100 adults over 60 showing that B. subtilis CU1 increases secretory IgA and reduces the frequency of winter respiratory infections. | ||||
| Piewngam P et al. | 2018 | Cohort Study | Nature | View on PubMed |
Pathogen elimination by probiotic Bacillus via signalling interference Study demonstrating that Bacillus subtilis inhibits Staphylococcus aureus colonization through interference with quorum-sensing, a natural bacterial competition mechanism. | ||||
| Elshaghabee FMF et al. | 2017 | Systematic Review | Frontiers in Microbiology | View on PubMed |
Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives Comprehensive review of evidence for Bacillus as a probiotic: mechanisms of action, safety profile, metabolite production and clinical perspectives. | ||||
| Cutting SM | 2011 | Systematic Review | Food Microbiology | View on PubMed |
Bacillus probiotics Review of probiotic properties of Bacillus subtilis and related species: gastric survival, enzyme production and clinical data in humans. | ||||
| Hong HA et al. | 2005 | Systematic Review | FEMS Microbiology Reviews | View on PubMed |
The use of bacterial spore formers as probiotics Foundational article describing the advantages of spore-forming probiotics (stability, gastric survival, metabolite production) over conventional vegetative probiotics. | ||||
| Mehta A et al. | 2025 | Randomised Controlled Trial | Beneficial Microbes | View on PubMed |
Effects of spore-forming probiotic Bacillus subtilis HU58 in children with antibiotic-associated diarrhoea: a randomised, double-blind, placebo-controlled trial Double-blind randomised controlled trial in 68 children (1-12 years) with antibiotic-associated diarrhoea. B. subtilis HU58 (2 × 10⁹ CFU/day) normalised stools in 93.5% of subjects by day 3 (vs 22.6% placebo) and significantly reduced abdominal pain. | ||||
| Yossef M et al. | 2020 | Pilot Study | Evidence-Based Complementary and Alternative Medicine | View on PubMed |
An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy Double-blind pilot study in 40 patients with hepatic encephalopathy showing that B. subtilis HU58 is well tolerated over 4 weeks and significantly reduces blood ammonia in patients with baseline levels above 60 µg/dL. | ||||
| Dahl WJ et al. | 2020 | In Vitro Study | Microorganisms | View on PubMed |
Bacillus subtilis HU58 and Bacillus coagulans SC208 Probiotics Reduced the Effects of Antibiotic-Induced Gut Microbiome Dysbiosis in an M-SHIME Model M-SHIME model simulating the human intestinal microbial ecosystem: B. subtilis HU58 reduces the effects of clindamycin-induced dysbiosis, restores microbial diversity and maintains butyrate production following antibiotic treatment. | ||||